Francis Burrows
Known title: Chief Scientific OfficerCIK: 0002051119
Associated companies
Transaction History
| KURA | ▼ Sell | Open Market | 1,311 | $11K | 1/27/2026 | View on chart |
| KURA | ▲ Buy | Option Exercise | 35,000 | $168K | 12/18/2025 | View on chart |
| KURA | ▼ Sell | Open Market | 23,726 | $232K | 12/18/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project
Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project. Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.